Merck Faces Varicella-Zoster Virus Supply Shortage For Vaccine Production
Executive Summary
Merck does not expect problems in the production of bulk varicella-zoster virus vaccine to affect near-term supplies of individual products that contain the virus - the varicella vaccine Varivax, the herpes zoster vaccine Zostavax, and the measles, mumps, rubella and varicella (MMR-V) combination ProQuad
You may also be interested in...
Zostavax Gets Nod For Younger Age Group, But Supply Issues Make Sales Boost Unlikely
Merck's ability to capitalize on FDA approval of the shingles vaccine in patients ages 50-59 years is questionable given ongoing supply constraints.
Merck Recalls PedvaxHIB Vaccine, Sanofi Steps Up Production To Fill Void
Merck's voluntary recall of its PedvaxHIB vaccine is causing a short-term shortage of Haemophilus influenza type b vaccine supply in the U.S
Merck Recalls PedvaxHIB Vaccine, Sanofi Steps Up Production To Fill Void
Merck's voluntary recall of its PedvaxHIB vaccine is causing a short-term shortage of Haemophilus influenza type b vaccine supply in the U.S